Palantir's Commercial Surge Nears Government Scale, But Valuation Leaves No Room for Error

What happened

Palantir's commercial business is now nearly as large as its government segment, with U.S. commercial revenue within $45 million of U.S. government revenue, marking a shift from its traditional defense-centric model. The Motley Fool article questions whether the stock is a buy at 94 times sales, highlighting the potential for a second growth engine but implicitly acknowledging the extremely high valuation. Palantir's latest financials show exceptional fundamentals: Q2 2026 revenue of $1.94 billion, 93% year-over-year growth, 85% gross margin, and strong free cash flow, yet the stock trades at 147 times earnings and 253 times EV/EBITDA. The master report's key concern is whether headline total contract value (TCV) and remaining deal value (RDV) convert into auditable backlog, as company-wide RPO remains only $4.9 billion with many contracts terminable for convenience. Thus, while the commercial surge is real, the stock's valuation leaves little room for execution slippage, and the balance of risk remains skewed to the downside in the near term.

Implication

The commercial near-parity is positive but not new information; it was already reflected in the latest filings and market sentiment. The primary investment risk is not demand but conversion: commercial deals and government awards must turn into funded, recognized revenue to justify the multiple. With RPO at $4.9 billion and a high share of revenue from U.S. customers, any slowdown in conversion or procurement delays could compress the multiple sharply. The company's fortress balance sheet provides downside protection for operations but not for the stock if growth expectations reset. Therefore, a disciplined approach favors waiting for either a price near the attractive entry of $155 or two consecutive quarters showing RPO and deferred revenue growth in line with bookings.

Thesis delta

The news article reinforces the existing thesis that U.S. commercial demand is strong and becoming a second engine. However, it does not alter the core concern that the stock's valuation prices in flawless execution. The thesis remains a WAIT, with the same conditions for upgrade or downgrade unchanged: continued evidence of backlog conversion would support a more constructive stance, but until then, the risk/reward is unattractive.